NeuroMetrix Inc NURO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NURO is a good fit for your portfolio.
News
-
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
-
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
-
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
-
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
-
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
-
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
-
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
Trading Information
- Previous Close Price
- $3.65
- Day Range
- $4.03–4.41
- 52-Week Range
- $2.73–11.52
- Bid/Ask
- $4.27 / $4.42
- Market Cap
- $8.74 Mil
- Volume/Avg
- 195,156 / 45,463
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.neurometrix.com
Valuation
|
Metric
|
NURO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.28 |
Price/Sales | 0.64 |
Price/Cash Flow | — |
Price/Earnings
NURO
Financial Strength
|
Metric
|
NURO
|
|---|---|
Quick Ratio | 14.92 |
Current Ratio | 16.81 |
Interest Coverage | — |
Quick Ratio
NURO
Profitability
|
Metric
|
NURO
|
|---|---|
Return on Assets (Normalized) | −27.23% |
Return on Equity (Normalized) | −29.01% |
Return on Invested Capital (Normalized) | −29.80% |
Return on Assets
NURO
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Dkhnsfz | Mjbzcyr | $182.7 Bil | |
SYK
| Stryker Corp | Pyphdzfvg | Qgq | $124.6 Bil | |
MDT
| Medtronic PLC | Bqbghnl | Zftvfh | $105.2 Bil | |
BSX
| Boston Scientific Corp | Xwcwlpw | Dsnlf | $99.1 Bil | |
EW
| Edwards Lifesciences Corp | Vtdqfvzxrm | Qwvvl | $52.0 Bil | |
DXCM
| DexCom Inc | Xgkqrcyr | Bpp | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Fmyzbxmns | Ygvw | $24.5 Bil | |
ALGN
| Align Technology Inc | Vhbxbkyxd | Wslgxj | $22.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Nkfgshsdf | Tnpxqpr | $18.3 Bil | |
PODD
| Insulet Corp | Zgdcvwqhd | Rmkvrr | $11.6 Bil |